FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2586988026> ?p ?o ?g. }

• W2586988026 endingPage "566" @default.
• W2586988026 startingPage "559" @default.
• W2586988026 abstract "ObjectivesThe aim was to assess the efficacy and safety of alprostadil in patients with peripheral arterial occlusive disease (PAOD) Fontaine Stage IV.MethodsThis was a multinational, prospective, randomised, double blind, placebo controlled, parallel group trial. Patients with Stage IV PAOD were equally randomised to either 4 weeks of alprostadil treatment twice daily or to placebo treatment twice daily. The primary efficacy variables were the rate of complete healing of all necrosis and ulceration 12 weeks after the end of treatment and the frequency of major amputations 24 weeks after the end of treatment.ResultsA total of 840 patients were randomised between 2004 and 2013. At baseline, no major differences between treatment groups were found. The rate of “complete healing” was 18.4% in patients on alprostadil and 17.2% in patients on placebo. The rates of “major amputations” were 12.6% in patients on alprostadil and 14.6% in patients on placebo. The adjusted difference between alprostadil and placebo including their 95% confidence intervals was 1.1 (−4.0 to 6.3) for “complete healing” and −2.1 (−6.7 to 2.5) for “major amputations.” In the subgroup of diabetic patients the rates of major amputations were numerically lower in the alprostadil than placebo group (10.6% vs. 17.4%). Within the total cohort a non-significant difference in “decrease in ulcer area ≥50%” was reached in 30.2% of patients on alprostadil and in 24.3% of patients on placebo at end of treatment.ConclusionsIn this study, superiority of alprostadil over placebo could not be shown. Nevertheless, a slight numerical but not clinically relevant advantage for alprostadil emerged from the “area decrease of ulcers by ≥ 50%,” indicating that a healing effect may have started. The results have to be considered in the light of several limitations in study design and conduct. The aim was to assess the efficacy and safety of alprostadil in patients with peripheral arterial occlusive disease (PAOD) Fontaine Stage IV. This was a multinational, prospective, randomised, double blind, placebo controlled, parallel group trial. Patients with Stage IV PAOD were equally randomised to either 4 weeks of alprostadil treatment twice daily or to placebo treatment twice daily. The primary efficacy variables were the rate of complete healing of all necrosis and ulceration 12 weeks after the end of treatment and the frequency of major amputations 24 weeks after the end of treatment. A total of 840 patients were randomised between 2004 and 2013. At baseline, no major differences between treatment groups were found. The rate of “complete healing” was 18.4% in patients on alprostadil and 17.2% in patients on placebo. The rates of “major amputations” were 12.6% in patients on alprostadil and 14.6% in patients on placebo. The adjusted difference between alprostadil and placebo including their 95% confidence intervals was 1.1 (−4.0 to 6.3) for “complete healing” and −2.1 (−6.7 to 2.5) for “major amputations.” In the subgroup of diabetic patients the rates of major amputations were numerically lower in the alprostadil than placebo group (10.6% vs. 17.4%). Within the total cohort a non-significant difference in “decrease in ulcer area ≥50%” was reached in 30.2% of patients on alprostadil and in 24.3% of patients on placebo at end of treatment. In this study, superiority of alprostadil over placebo could not be shown. Nevertheless, a slight numerical but not clinically relevant advantage for alprostadil emerged from the “area decrease of ulcers by ≥ 50%,” indicating that a healing effect may have started. The results have to be considered in the light of several limitations in study design and conduct." @default.
• W2586988026 created "2017-02-17" @default.
• W2586988026 creator A5003659498 @default.
• W2586988026 creator A5021705851 @default.
• W2586988026 creator A5030674018 @default.
• W2586988026 creator A5055302317 @default.
• W2586988026 creator A5057842104 @default.
• W2586988026 creator A5057843389 @default.
• W2586988026 creator A5079025466 @default.
• W2586988026 creator A5080408530 @default.
• W2586988026 date "2017-04-01" @default.
• W2586988026 modified "2023-10-01" @default.
• W2586988026 title "Efficacy and Safety of Alprostadil in Patients with Peripheral Arterial Occlusive Disease Fontaine Stage IV: Results of a Placebo Controlled Randomised Multicentre Trial (ESPECIAL)" @default.
• W2586988026 cites W2021473250 @default.
• W2586988026 cites W2028754364 @default.
• W2586988026 cites W2075372933 @default.
• W2586988026 cites W2078829390 @default.
• W2586988026 cites W2108465511 @default.
• W2586988026 cites W2185467918 @default.
• W2586988026 cites W2887712073 @default.
• W2586988026 cites W3171237122 @default.
• W2586988026 cites W4236938366 @default.
• W2586988026 cites W4240395060 @default.
• W2586988026 doi "https://doi.org/10.1016/j.ejvs.2016.12.035" @default.
• W2586988026 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28189475" @default.
• W2586988026 hasPublicationYear "2017" @default.
• W2586988026 type Work @default.
• W2586988026 sameAs 2586988026 @default.
• W2586988026 citedByCount "25" @default.
• W2586988026 countsByYear W25869880262017 @default.
• W2586988026 countsByYear W25869880262018 @default.
• W2586988026 countsByYear W25869880262019 @default.
• W2586988026 countsByYear W25869880262020 @default.
• W2586988026 countsByYear W25869880262021 @default.
• W2586988026 countsByYear W25869880262022 @default.
• W2586988026 countsByYear W25869880262023 @default.
• W2586988026 crossrefType "journal-article" @default.
• W2586988026 hasAuthorship W2586988026A5003659498 @default.
• W2586988026 hasAuthorship W2586988026A5021705851 @default.
• W2586988026 hasAuthorship W2586988026A5030674018 @default.
• W2586988026 hasAuthorship W2586988026A5055302317 @default.
• W2586988026 hasAuthorship W2586988026A5057842104 @default.
• W2586988026 hasAuthorship W2586988026A5057843389 @default.
• W2586988026 hasAuthorship W2586988026A5079025466 @default.
• W2586988026 hasAuthorship W2586988026A5080408530 @default.
• W2586988026 hasBestOaLocation W25869880261 @default.
• W2586988026 hasConcept C126322002 @default.
• W2586988026 hasConcept C141071460 @default.
• W2586988026 hasConcept C142724271 @default.
• W2586988026 hasConcept C168563851 @default.
• W2586988026 hasConcept C188816634 @default.
• W2586988026 hasConcept C204243189 @default.
• W2586988026 hasConcept C204787440 @default.
• W2586988026 hasConcept C27081682 @default.
• W2586988026 hasConcept C2776204877 @default.
• W2586988026 hasConcept C42219234 @default.
• W2586988026 hasConcept C44249647 @default.
• W2586988026 hasConcept C535046627 @default.
• W2586988026 hasConcept C71924100 @default.
• W2586988026 hasConceptScore W2586988026C126322002 @default.
• W2586988026 hasConceptScore W2586988026C141071460 @default.
• W2586988026 hasConceptScore W2586988026C142724271 @default.
• W2586988026 hasConceptScore W2586988026C168563851 @default.
• W2586988026 hasConceptScore W2586988026C188816634 @default.
• W2586988026 hasConceptScore W2586988026C204243189 @default.
• W2586988026 hasConceptScore W2586988026C204787440 @default.
• W2586988026 hasConceptScore W2586988026C27081682 @default.
• W2586988026 hasConceptScore W2586988026C2776204877 @default.
• W2586988026 hasConceptScore W2586988026C42219234 @default.
• W2586988026 hasConceptScore W2586988026C44249647 @default.
• W2586988026 hasConceptScore W2586988026C535046627 @default.
• W2586988026 hasConceptScore W2586988026C71924100 @default.
• W2586988026 hasFunder F4320337846 @default.
• W2586988026 hasIssue "4" @default.
• W2586988026 hasLocation W25869880261 @default.
• W2586988026 hasLocation W25869880262 @default.
• W2586988026 hasOpenAccess W2586988026 @default.
• W2586988026 hasPrimaryLocation W25869880261 @default.
• W2586988026 hasRelatedWork W2003938723 @default.
• W2586988026 hasRelatedWork W2017587608 @default.
• W2586988026 hasRelatedWork W2039865683 @default.
• W2586988026 hasRelatedWork W2047967234 @default.
• W2586988026 hasRelatedWork W2056697517 @default.
• W2586988026 hasRelatedWork W2088544186 @default.
• W2586988026 hasRelatedWork W2111682929 @default.
• W2586988026 hasRelatedWork W2439875401 @default.
• W2586988026 hasRelatedWork W2536895331 @default.
• W2586988026 hasRelatedWork W2766370439 @default.
• W2586988026 hasVolume "53" @default.
• W2586988026 isParatext "false" @default.
• W2586988026 isRetracted "false" @default.
• W2586988026 magId "2586988026" @default.
• W2586988026 workType "article" @default.